The iShares Biotechnology ETF is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names.
The iShares U.S. Treasury Bond ETF holds only U.S. Treasury notes and bonds across the maturity curve, providing the cleanest expression of flight-to-quality stability in a single ticker. Credit risk is effectively zero because every holding carries the full faith and credit of the U.S. government.
Annaly's dividend coverage is tight but intact. The company paid $0.70 per share quarterly throughout 2025, and its non-GAAP earnings available for distribution covered that payout in every quarter, ranging from $0.72 to $0.73 per share.
The Value ETF tracks the CRSP US Large Cap Value Index, focusing on large-capitalization value stocks. It holds positions in a diversified set of companies, with recent data indicating around 312 stocks in total. Rather than the large tech stocks found propping up the portfolios of other ETFs, such as the Vanguard S&P 500 ETF or the Vanguard Total Stock Market ETF, its largest positions emphasize traditional value sectors rather than high-growth momentum.
The fund blends high yield corporate bonds, senior loans, and debt tranches of U.S. collateralized loan obligations (CLOs) into a single actively managed portfolio, aiming to deliver income that beats the broad bond market while keeping volatility lower than any single segment on its own.
Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) generates income by holding a diversified portfolio of dividend-paying U.S. stocks and passing those dividends directly to shareholders. With $88.5 billion in assets and an ultra-low 0.06% expense ratio, VYM offers cost-efficient exposure to companies that consistently return cash to investors. The fund currently yields 2.45%, slightly above the S&P 500's typical yield, while maintaining a 19-year uninterrupted payment history since its November 10, 2006 inception.